All News
@gurdeep_dulay I ask the same question always, why would you stop denosumab? Nothing comes close to fully ameliorating the negative consequences of doing so. Denosumab is for life, until we figure out how to safely get off it. Don't start it unless that is acceptable #ACR23
Richard Conway ( View Tweet)
Fantastic presentation by @sharoncowley01 🚀
~1/5 patients with PMR have US evidence of Vasculitis at time of diagnosis without clinical signs of GCA
⬆️role of US in these patients https://t.co/wSs3IB8SU7 https://t.co/mAhFDVJJ8T
Caoilfhionn Connolly ( View Tweet)
The places to look for #enthesitis in #PsA in foot/ankle
#ACR2023 https://t.co/KxD7i5l5gS
Dr Gurdeep S Dulay ( View Tweet)
Super interesting study re: impact of ORAL SURVEILLANCE on prescribing
Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD)
I know many have mixed feelings, but I believe in the risk & support this type of shift
@RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1
Mike Putman EBRheum ( View Tweet)
ABS0450
⭐️Baricitinib non-inferior as well as superior to TNFi in terms of ACR50 response @ 12w in real world csDMARD refractory RA patients
➡️open-label, T2T w/ Baricitinib (n=102) vs TNFi (n=97)
➡️DAS28-CRP remission (<0.6) in 74% of Bari vs 47% of TNFi
#ACR23 @RheumNow https://t.co/yydS20hNzM
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
No more underpowered long-term safety studies
We need a "SELECT-SURVEILLANCE" study to replicate ORAL-SURVEILLANCE & tell us if UPA has the same MACE/cancer risk as TOFA
Minus that, I plan to go 100% TOFA when it becomes generic in 2026
@RheumNow #ACR23 Abstr1326 https://t.co/LyQ1Q8qReO
Mike Putman EBRheum ( View Tweet)
AS pts on UPA for 52 wks who were active or healthy weight/underweight at BL generally experienced greater decreases from BL in ASDAS-CRP and BASDAI vs pts who were inactive or overweight/obese. #ACR23 Abs #0540 https://t.co/OfgbmYUoAu @rheumno https://t.co/liptgbK2hJ
Dr. Rachel Tate ( View Tweet)
#ACR23
#SGLT2 inhibitors assoc with
⬇️ urate
⬇️ flares if #gout
⬇️mortality
impact on #metabolicSyndrome ✅ https://t.co/ZIqDqirqar
Dr Gurdeep S Dulay ( View Tweet)
#ACR23
Scleroderma renal Crisis (SRC)
May precede skin involvement also.
RISK FACTORS
• Early diffuse skin disease
- 2-3 years from SSc onset, median 8 months
• Anti-RNA polymerase III (60%)
• Use of corticosteroids
- >15 mg/d or low doses for longer time https://t.co/RSIxEXLdX7
Aditya Burje AdityaBurje ( View Tweet)
#ACR23 Abstr#0785 So many debates re: HCQ dose 5mg/kg/d vs 6.5mg/kg/d - could blood monitoring help? A cohort study showed HCQ levels 750-1100 ng/mL was associated with reduced risk of #lupus activity by 76-90%. Need validation & assoc with retinal toxicity risk @RheumNowNews https://t.co/oRCHUG2dVA
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr#0548 Is there a risk prediction tool to help exclude non-immune pathology for Rheumatologists with newly referred ANA+? 3-yr data showed 3 BL markers: IFN score B, criteria No & FH of RMD had 98% specificity. Cd help inform early Tx trials in High Risk @RheumNowNews https://t.co/DCAg4EwM9d
Md Yuzaiful Md Yusof ( View Tweet)
TNF AND IL17 was equally effective in Axial SpA!
#ACR23 #Reviewcourse https://t.co/oofQkvsJ3f
Nouf Al hemmadi ( View Tweet)
Need to improve our conversations with young adults on methotrexate about alcohol and sexual activity. They are often uncomfortable and/or dishonest about telling. Great work from @McMasterU by undergrad Matthew Sholdice #transition @drgrainnemurray #ACR23 https://t.co/wwyZLQVA51
Catherine Hill CatherineL_Hill ( View Tweet)
Extrahepatic manifestations of #hepatitisC #ACR23 https://t.co/sb0AQofkvt
dr hanady manasfi hanadymanasfi ( View Tweet)
I would like to participate in a prospective trial for prevention on RA by pizza consumption. #ACR23 https://t.co/Y96xFolUgM
Adela Castro AdelaCastro222 ( View Tweet)
#ACR23 #ReviewCourse - By Dr. Francesco Boin. Systemic Sclerosis Screening for Organ Involvement. This slide is a true "take home slide" @ACRheum #ACRambassador https://t.co/4FVYWJjHyV
Anne Troldborg ( View Tweet)
Or to quote the great Murray Urowitz @UHN "a #lupus pregnancy has four trimesters"! #ACR23 https://t.co/Iw2S81tiTH
Ian N Bruce ( View Tweet)
✅ Question to YOU attending #ACR23 ➡️ We're almost at the end of 2023 ⌛and many great #lupus data are being presented at @ACRheum Convergence 2023 in San Diego 👍 What would YOU update/change 🔄 regarding the management of #lupus in 2024 compared to 2023? 🧭 https://t.co/xpSXjuDjyr
Laurent ARNAUD ( View Tweet)
Real-life data about the PEXIVAS reduced-dose glucocorticoid regimen in #granulomatosis with polyangiitis and microscopic #polyangiitis (Abstract 0725 https://t.co/7x34Hr0OMP)
@TerrierBen
#ACR23
#ACRambassador https://t.co/D8UfZvXQCl
Alessia Alunno ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on SpA Update: Radiographic and Non-Radiographic AS - Dr. Alexis Ogdie
1. Workup of inflammatory back pain: History, exam, CRP, HLA-B27, SI joint films, MRI pelvis (STIR images, no need for contrast). Response to NSAIDs not actually… https://t.co/M0W6UNsPxF https://t.co/7k3xl1RXZz
Paul Sufka, MD psufka ( View Tweet)